Tuberculosis in India – Evolution of National Programmes and Treatment Regimens
Keywords:
TB, ATT, MDR-TB, RR-TB, NTEP, DOTS-PLUS, NIKSHAY
Abstract
Tuberculosis (TB) has been one of the most important infectious diseases in India, and National Programs to streamline its diagnosis and management have been evolving and improving over time. With the highest TB burden in the world, India has been striving towards its goal of eliminating TB with greater awareness, involving physicians all over the country, improving patient access, introducing new drugs and diagnostic modalities for resistant TB, and also now creating a robust web-based platform. These commendable and immense strides keep the hope alive of India being TB-free in the future.
References
1. https://dghs.mohfw.gov.in/national-tuberculosis-elimination-programme.php
2. Mahadev B, Kumar P. History of tuberculosis control in India. J Indian Med Assoc. 2003 Mar;101(3):142-3.
3. https://tbcindia.mohfw.gov.in/wp-content/uploads/2023/05/4773363959TOG-Chapter-1-Introduction.pdf
4. Sachdeva KS, Kumar A, Dewan P, Kumar A, Satyanarayana S. New vision for Revised National Tuberculosis Control Programme (RNTCP): Universal access - "reaching the un-reached". Indian J Med Res. 2012 May;135(5):690-4.
5. Verma R, Khanna P, Mehta B. Revised national tuberculosis control program in India: the need to strengthen. Int J Prev Med. 2013 Jan;4(1):1-5.
6. Vishwakarma D, Gaidhane A, Sahu S, Rathod AS. Multi-Drug Resistance Tuberculosis (MDR-TB) Challenges in India: A Review. Cureus. 2023 Dec 9;15(12):e50222
7. Atre, Sachin; Padalkar, Dharmedra; Srivastava, Tanya; Rathod, Hetal; Chaugule, Hanumant; Patvekar, Meenal; Bhawalkar, Jitendra. Prevalence of Multidrug-Resistant Tuberculosis (MDR-TB) in India: A Mini Systematic Review and Meta-Analysis (2016–2022). Medical Journal of Dr.
D.Y. Patil Vidyapeeth 16(4):p 500-504, Jul–Aug 2023.
8. Mase SR, Chorba T. Treatment of Drug-Resistant Tuberculosis. Clin Chest Med. 2019 Dec;40(4):775-795.
9. WHO Consolidated guidelines on Drug Resistant Tuberculosis Treatment. Available from https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf
10. Yadav AK, Mehrotra AK, Agnihotri SP, Swami S. Study of factors influencing response and outcome of Cat-IV regimen in MDRTB patients. Indian J Tuberc. 2016 Oct;63(4):255-261.
11. Padmapriyadarsini C, Vohra V, Bhatnagar A, Solanki R, Sridhar R, Anande L, et al.; for BEAT India Team. Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis. Clin Infect Dis. 2022 Jun 29;76(3):e938–46.
12. Dev Bhattarai M. Universal drug-susceptibility testing of first-line drugs to preserve their efficacy: An essential strategy to defeat tuberculosis. J Clin Tuberc Other Mycobact Dis. 2023 Aug 22;33:100394.
13. Vijay DD, Meharaj SHS, Jayanthi S, et al. A Comparison Study of CBNAAT, Gene Xpert and Line Probe Assays in the Diagnosis of Tuberculosis in smear Negative Specimens. J Pure Appl Microbiol. 2022;16(3):1953-1963.
14. Auer C, Gupta A, Malbacius C, Ghafoor A, Kock Y, Medvedieva O, Hanlon P, Steinmann P, Juneja S. Savings from the introduction of BPaL and BPaLM regimens at the country level. IJTLD Open. 2024 Jul 1;1(7):314-319.
15. NTEP-Treatment algorithm for MDR/RR-TB. Available from https://ntep.in/node/1810/CP-treatment-algorithm-mdrrr-tb#:~:text=The%20treatment%20algorithm%20for%20Multidrug%2Dresistant/%20Rifampicin%2Dresistant%20TB,%2Dresistant%20Tuberculosis%20(PMDT).
2. Mahadev B, Kumar P. History of tuberculosis control in India. J Indian Med Assoc. 2003 Mar;101(3):142-3.
3. https://tbcindia.mohfw.gov.in/wp-content/uploads/2023/05/4773363959TOG-Chapter-1-Introduction.pdf
4. Sachdeva KS, Kumar A, Dewan P, Kumar A, Satyanarayana S. New vision for Revised National Tuberculosis Control Programme (RNTCP): Universal access - "reaching the un-reached". Indian J Med Res. 2012 May;135(5):690-4.
5. Verma R, Khanna P, Mehta B. Revised national tuberculosis control program in India: the need to strengthen. Int J Prev Med. 2013 Jan;4(1):1-5.
6. Vishwakarma D, Gaidhane A, Sahu S, Rathod AS. Multi-Drug Resistance Tuberculosis (MDR-TB) Challenges in India: A Review. Cureus. 2023 Dec 9;15(12):e50222
7. Atre, Sachin; Padalkar, Dharmedra; Srivastava, Tanya; Rathod, Hetal; Chaugule, Hanumant; Patvekar, Meenal; Bhawalkar, Jitendra. Prevalence of Multidrug-Resistant Tuberculosis (MDR-TB) in India: A Mini Systematic Review and Meta-Analysis (2016–2022). Medical Journal of Dr.
D.Y. Patil Vidyapeeth 16(4):p 500-504, Jul–Aug 2023.
8. Mase SR, Chorba T. Treatment of Drug-Resistant Tuberculosis. Clin Chest Med. 2019 Dec;40(4):775-795.
9. WHO Consolidated guidelines on Drug Resistant Tuberculosis Treatment. Available from https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf
10. Yadav AK, Mehrotra AK, Agnihotri SP, Swami S. Study of factors influencing response and outcome of Cat-IV regimen in MDRTB patients. Indian J Tuberc. 2016 Oct;63(4):255-261.
11. Padmapriyadarsini C, Vohra V, Bhatnagar A, Solanki R, Sridhar R, Anande L, et al.; for BEAT India Team. Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis. Clin Infect Dis. 2022 Jun 29;76(3):e938–46.
12. Dev Bhattarai M. Universal drug-susceptibility testing of first-line drugs to preserve their efficacy: An essential strategy to defeat tuberculosis. J Clin Tuberc Other Mycobact Dis. 2023 Aug 22;33:100394.
13. Vijay DD, Meharaj SHS, Jayanthi S, et al. A Comparison Study of CBNAAT, Gene Xpert and Line Probe Assays in the Diagnosis of Tuberculosis in smear Negative Specimens. J Pure Appl Microbiol. 2022;16(3):1953-1963.
14. Auer C, Gupta A, Malbacius C, Ghafoor A, Kock Y, Medvedieva O, Hanlon P, Steinmann P, Juneja S. Savings from the introduction of BPaL and BPaLM regimens at the country level. IJTLD Open. 2024 Jul 1;1(7):314-319.
15. NTEP-Treatment algorithm for MDR/RR-TB. Available from https://ntep.in/node/1810/CP-treatment-algorithm-mdrrr-tb#:~:text=The%20treatment%20algorithm%20for%20Multidrug%2Dresistant/%20Rifampicin%2Dresistant%20TB,%2Dresistant%20Tuberculosis%20(PMDT).
Published
2025-04-11
How to Cite
Dr. Desh Deepak, & Dr. Varsha Narayanan. (2025). Tuberculosis in India – Evolution of National Programmes and Treatment Regimens. The Indian Practitioner, 78(03), 5-8. Retrieved from https://articles.theindianpractitioner.com/index.php/tip/article/view/1874
Section
Editorial
